We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

Close

subscriber-only content

or
for more website access

The content of this section is only available to Investors Chronicle online subscribers.

Novartis breakthrough feeds Oxford BioMedica hopes

Followers of biotech group Oxford BioMedica (OXB) will be well aware of the drug development programme it's working on with Swiss giant Novartis (ch:NOVN). The two are working together to develop a drug called CTL019, which is designed to treat cancer patients suffering from a specific kind of lymphoma and leukaemia. The drug is due to be submitted for regulatory approval before the end of this year - and the US Food and Drug Administration (FDA) just handed Novartis a golden ticket.

subscriber-only content

visible-status-Subscription-Only story-url-Oxford Biomedica_news_18_4_17.xml

By Harriet Russell,
18 April 2017

Print this article
Comments

Share Price

IC columnists

Simon Thompson

Simon Thompson

Winning stock and trading ideas from the creator of the Bargain Portfolio

The Trader

The Trader

Technical analysis and market calls from our in-house charting expert

Mr Bearbull

Mr Bearbull

Sound ideas on running portfolios from an experienced commentator

Smart Money

Smart Money

Practical ideas to help you plan your future

Chris Dillow

Chris Dillow

Incisive economic commentary plus thoughts on investor behaviour

Property Matters

Property Matters

Comment on the ups and downs of property investments, with a particular focus on the perennially popular world of buy to let

The Editor

The Editor

Commentary on markets, world affairs and everything to do with investing

Chronic Investor Blog

Chronic Investor Blog

Our light-hearted take on the world of investing

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply